These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6693780)

  • 1. A new liquid formulation of 8-methoxypsoralen: bioactivity and effect of diet.
    Levins PC; Gange RW; Momtaz-T K; Parrish JA; Fitzpatrick TB
    J Invest Dermatol; 1984 Feb; 82(2):185-7. PubMed ID: 6693780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
    Treffel P; Makki S; Humbert P; Khaldoun H; Agache P
    Acta Derm Venereol; 1992; 72(1):65-7. PubMed ID: 1350152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of food on 8-methoxypsoralen serum concentration and minimal phototoxic dose.
    Bech-Thomsen N; Angelo HR; Knudsen EA
    Br J Dermatol; 1992 Dec; 127(6):620-4. PubMed ID: 1476921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary intake and risk assessment of phototoxic furocoumarins in humans.
    Schlatter J; Zimmerli B; Dick R; Panizzon R; Schlatter C
    Food Chem Toxicol; 1991 Aug; 29(8):523-30. PubMed ID: 1894218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
    Tanew A; Kipfelsperger T; Seeber A; Radakovic-Fijan S; Hönigsmann H
    J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of methoxsalen dose on ultraviolet-A-induced erythema.
    Ibbotson SH; Dawe RS; Farr PM
    J Invest Dermatol; 2001 May; 116(5):813-5. PubMed ID: 11348476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
    Nimkulrat P; Leenutaphong V; Sudtim S
    J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response relations in phototoxicity due to 8-methoxypsoralen and UV-A in man.
    Ljunggren B; Bjellerup M; Carter DM
    J Invest Dermatol; 1981 Feb; 76(2):73-5. PubMed ID: 7462679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polychromatic action spectrum for photosensitivity to orally administered 8-methoxypsoralen in humans.
    Bech-Thomsen N; Wulf HC
    Clin Exp Dermatol; 1994 Jan; 19(1):12-5. PubMed ID: 8313631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of a new oral methoxsalen formulation. A serum concentration and photosensitivity response study.
    Sullivan TJ; Walter JL; Kouba RF; Maiwald DC
    Arch Dermatol; 1986 Jul; 122(7):768-71. PubMed ID: 3729509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
    Grundmann-Kollmann M; Tegeder I; Ochsendorf FR; Zollner TM; Ludwig R; Kaufmann R; Podda M
    Br J Dermatol; 2001 May; 144(5):991-5. PubMed ID: 11359386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An action spectrum for photoinduction of prolonged cutaneous photosensitivity by topical 8-MOP.
    Gold RL; Anderson RR; Natoli VD; Gange RW
    J Invest Dermatol; 1988 Jun; 90(6):818-22. PubMed ID: 3373013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
    Shephard SE; Langguth P; Panizzon RG
    Photodermatol Photoimmunol Photomed; 2001 Feb; 17(1):11-21. PubMed ID: 11169171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An action spectrum for the elicitation of erythema in skin persistently sensitized by photobound 8-methoxypsoralen.
    Ortel B; Gange RW
    J Invest Dermatol; 1990 Jun; 94(6):781-5. PubMed ID: 2355181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of minimal phototoxic dose and skin type for determining initial UVA dose in oral liquid methoxsalen photochemotherapy for the treatment of psoriasis.
    Rafal ES; Hamilton TA; Gonzalez E
    J Invest Dermatol; 1991 Dec; 97(6):1048-52. PubMed ID: 1748814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
    Herfst MJ; De Wolff FA
    Br J Clin Pharmacol; 1982 Apr; 13(4):519-22. PubMed ID: 7066167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythema action spectrum of topical 8-methoxypsoralen-sensitized skin re-evaluated: implications for routine clinical practice.
    Al-Ismail D; Edwards C; Anstey AV
    Br J Dermatol; 2016 Jan; 174(1):131-5. PubMed ID: 26383592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of 8-methoxypsoralen in two different drug preparations: correlation with photosensitivity and UV-A dose requirements for photochemotherapy.
    Hönigsmann H; Jaschke E; Nitsche V; Brenner W; Rauschmeier W; Wolff K
    J Invest Dermatol; 1982 Oct; 79(4):233-6. PubMed ID: 7130741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.